Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa

Saudi Medical Journal

Volumn 25, Issue 6, 2004, Pages 780-784

  Al Jasser, Asma M ^a   Elkhizzi, Noura A ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DATA BASE; DRUG CHOICE; EMPIRICISM; GRAM NEGATIVE INFECTION; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PUBLIC HOSPITAL; RESPIRATORY SYSTEM; SAUDI ARABIA; SURGICAL PATIENT;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES;

EID: 3042856286     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Centre for Disease Control and Prevention. National Nosocomial Infectious Surveillance (NNIS) system report: data summary from October 1986 to April 1998, issued June 1998. Am J Infect Control 1998; 26: 522-533.
2. Diekma DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC et al. Survey of blood-stream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada and Latin America for the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1999; 29: 595-607.
3. Vincent JL, Bihari DL, Suter PM, Bruining HA, White J, Nicolas-chanion M et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 1995; 74; 639-644.
4. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Vol 2. Philadelphia (PA): Churchill Livingstone; 2000. p. 2310-2335.
5. Grundmann H, Kropec A, Hartung D, Berner R, Daschner F. Pseudomonas aeruginosa in a neonatal intensive care unit: reservoirs and ecology of nosocomial pathogen. J Infect Dis 1993; 168: 943-947.
6. Moss RB. Cystic Fibrosis: pathogenesis, pulmonary infection and treatment. Clin Infect Dis 1995; 21: 839-845.
7. Rolston KV, Tarrand JJ. Pseudomonas aeruginosa - still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer centre. Clin Infect Dis 1999; 29: 463-464.
8. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other non-fermentative gram-negative bacteria. Clin Infect Dis 1998; 27 (Suppl 1): S93-S99.
9. Livermore MD. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
10. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002; 49: 229-233.
11. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127-1132.
12. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-1382.
13. Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz MS. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. Antimicrob Agents Chemother 1999; 43: 81-82.
14. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility testing. Document M2-A7. Wayne (PA): NCCLS; 2000.
15. National Committee for Clinical Laboratory Standards (NCCLS). Performance standard for antimicrobial susceptibility testing. Document M100-S11. Wayne (PA): NCCLS; 2001.
16. Saiman L, Schidlow D, Smith A, editors. Concepts in care: microbiology and infectious disease in cystic fibrosis. Vol V. Bethesda (MD): Cystic Fibrosis Foundation; 1994.
17. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-215.
18. Intensive Care Antimicrobial Resistance Epidemiology (ICARE). Surveillance report data summary from Jannuary 1996 through December 1997. A report from the National Nosocomial Infections Surveillance (NNIS) system. Am J Infect Control 1999; 27: 279-284.
19. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY antimicrobial surveillance program 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S146-S155.
20. Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. J Antimicrob Chemother 2000; 46: 4-23.
21. Naka T, Nakajima A, Ono T, Saito K, Yoneyama H. Resistance to beta-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the Mex AB-Oprm efflux pump and beta-lactamase. Antimicrob Agents Chemother 1999; 43: 1301-1303.
22. Livermore DM. Of pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-250.
23. Pai H, Kim JW, Kim J, Lee JH, Choc Kw, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agent Chemother 2001; 45: 480-484.
24. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094-1098.
25. Iaconis J, Pitkin DH, Sheikh W, Nadler HL. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997; 24 (Suppl 2): 191-196.
26. Harris AD, Perencevich E, Roughmann MC, Morris G, Kaye KS, Johnson JA. Risk factors for piperacillin/tazobactam resistant Pseudomonas aeurginosa among hospitalized patients. Antimicrob Agents Chemother 2002; 46: 854-858.
27. Mokaddas EM, Sanyal SC. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam. J Chemother 1999; 11: 97-102.
28. Lee SC, Fung CP, Liu Pr, Wang TC, See L, Lee N et al. Nosocomial infections with ceftazidime resistant Pseudomonas aeruginosa risk factors and outcome. Infect Control Hosp Epidemiol 1999; 20: 205-207.
29. Fluit AC, Verhoef J, Schmitz FJ, The European SENTRY Participants. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. Eur J Clin Microbial Infect Dis 2000; 19: 370-374.
30. Harris A, Torres-Viera C, Venkataraman L, Degirolami P, Samose M, Carmeli Y. Epidemiology and clinical outcomes of patients with multi-resistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28: 1128-1133.
31. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic Fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-537.
32. Levin AS, Barone AA, Peng J, Santos MV, Marinho IS, Arruda E et al. Intravenous colistin therapy for nosocomial infections caused by multidrug-resistant Pseudomonas and Acinetobacter Baumannii. Clin Infect Dis 1999; 28: 1008-1011.
33. Arruda EA, Marinho IS, Boulos M, Sinto SI, Caiaffa H, Mendes CM et al. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 1999; 20: 620-623.
34. Panzig B, Schroder G, Pitten FA, Grundling MA. Large outbreak of multiresistant Pseudomonas aeruginosa strains in Northeastern Germany. J Antimicrob Chemother 1999; 43: 415-418.
35. Srikumar R, Tsang E, Pole K. Contribution of MexAB Opr M multidrug efflux system to the beta-lactam resistance of penicillin binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa. J Animrob Chemother 1999; 44: 537-540.